Motilal Oswal's research report on Atul
ATLP reported revenue below our estimates, with both the Life Science Chemicals and Performance & Other Chemicals segments posting a decline in revenues QoQ (up 24% YoY, down 19% YoY, respectively). Gross margin was at 47.2% in 3QFY23 with EBITDAM declining 120bp QoQ to 13.6%. While contribution from the Life Science Chemicals segment to EBIT has improved significantly to 82% in 3QFY23 (from 67% in 2QFY23), contribution from the Performance & Other Chemicals to overall EBIT declined to 16% in 3QFY23 (from 34% in 2QFY23).
Outlook
We build in a revenue/EBIDTA/PAT CAGR of 9%/8%/7%, respectively, over FY22-25E. We value the stock at 35x Dec’24E EPS to arrive at a TP of INR8,328. On a one-year forward basis, ATLP trades at 33.9x. We reiterate our Neutral rating on the stock due to its limited upside potential.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.